summarize the lab results

Patient Thomas Court (TEST-THOMAS-COURT) is currently active with a latest assessment dated June 6, 2025. The primary phenotype is identified as mitochondrial dysfunction, with a secondary phenotype of neuroinflammation. The patient is in the recovery stage and is currently in an intake-only phase, with a confidence level of 54. The top scores for the patient are as follows: mitochondrial dysfunction at 67, neuroinflammation at 48, and mold CIRS pattern at 34 [1]. This summary is for decision support purposes only and not a directive.

The lab results for patient Thomas Court (TEST-THOMAS-COURT) indicate the following: - **Primary Phenotype**: Mitochondrial dysfunction - **Secondary Phenotype**: Neuroinflammation - **Recovery Stage**: Intake only - **Confidence Level**: 54 - **Top Scores**: - Mitochondrial dysfunction: 67 - Neuroinflammation: 48 - Mold CIRS pattern: 34 [1]. This summary reflects the patient's current status and phenotype scores, which may be relevant for further clinical evaluation and management. Remember, this is decision support, not a directive.

The lab results for patient Thomas Court (TEST-THOMAS-COURT) indicate the following: - **Primary Phenotype**: Mitochondrial dysfunction - **Secondary Phenotype**: Neuroinflammation - **Recovery Stage**: Intake only - **Confidence Level**: 54 **Top Scores**: - Mitochondrial Dysfunction: 67 - Neuroinflammation: 48 - Mold CIRS Pattern: 34 These results suggest a significant emphasis on mitochondrial dysfunction and neuroinflammation in the patient's condition, with the highest score in mitochondrial dysfunction indicating a potential area of focus for further assessment or intervention [1]. Please remember that this is decision support information and not a directive.